RS64840B1 - Cistein proteaza - Google Patents
Cistein proteazaInfo
- Publication number
- RS64840B1 RS64840B1 RS20231088A RSP20231088A RS64840B1 RS 64840 B1 RS64840 B1 RS 64840B1 RS 20231088 A RS20231088 A RS 20231088A RS P20231088 A RSP20231088 A RS P20231088A RS 64840 B1 RS64840 B1 RS 64840B1
- Authority
- RS
- Serbia
- Prior art keywords
- ides
- seq
- igg
- polypeptide
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/2201—Streptopain (3.4.22.10)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201502305A GB201502305D0 (en) | 2015-02-12 | 2015-02-12 | Protein |
| EP16704223.3A EP3256579B1 (en) | 2015-02-12 | 2016-02-12 | Cysteine protease |
| PCT/EP2016/053054 WO2016128559A1 (en) | 2015-02-12 | 2016-02-12 | Cysteine protease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS64840B1 true RS64840B1 (sr) | 2023-12-29 |
Family
ID=52781455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20231088A RS64840B1 (sr) | 2015-02-12 | 2016-02-12 | Cistein proteaza |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10758597B2 (enExample) |
| EP (2) | EP4265719A1 (enExample) |
| JP (1) | JP6879921B2 (enExample) |
| KR (1) | KR102524594B1 (enExample) |
| CN (2) | CN107532158A (enExample) |
| AU (1) | AU2016217801B2 (enExample) |
| BR (1) | BR112017017286A2 (enExample) |
| CA (1) | CA2976016C (enExample) |
| CL (1) | CL2017002066A1 (enExample) |
| CO (1) | CO2017009060A2 (enExample) |
| DK (1) | DK3256579T5 (enExample) |
| EA (1) | EA035896B1 (enExample) |
| ES (1) | ES2962794T3 (enExample) |
| FI (1) | FI3256579T3 (enExample) |
| GB (1) | GB201502305D0 (enExample) |
| HR (1) | HRP20231496T1 (enExample) |
| HU (1) | HUE064122T2 (enExample) |
| IL (1) | IL253939B (enExample) |
| LT (1) | LT3256579T (enExample) |
| MX (1) | MX391632B (enExample) |
| MY (1) | MY187486A (enExample) |
| PL (1) | PL3256579T3 (enExample) |
| PT (1) | PT3256579T (enExample) |
| RS (1) | RS64840B1 (enExample) |
| SG (1) | SG11201706349YA (enExample) |
| SI (1) | SI3256579T1 (enExample) |
| WO (1) | WO2016128559A1 (enExample) |
| ZA (1) | ZA201705114B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| CN108410798A (zh) * | 2018-03-27 | 2018-08-17 | 福建三造血技术有限公司 | 细胞分离用微珠洗脱液及配制方法 |
| MX2020010465A (es) | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| CA3095179A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| BR112020020266A2 (pt) | 2018-04-03 | 2021-01-19 | Stridebio, Inc. | Vetores de vírus com evasão de anticorpos |
| WO2020102740A2 (en) * | 2018-11-16 | 2020-05-22 | Spark Therapeutics, Inc. | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| CN113544278A (zh) * | 2019-01-28 | 2021-10-22 | 杜克大学 | 用于逃避体液免疫的组合物和方法 |
| CN113727992A (zh) | 2019-03-21 | 2021-11-30 | 斯特里迪比奥公司 | 重组腺相关病毒载体 |
| DE102019112558A1 (de) | 2019-05-14 | 2020-11-19 | Claas Selbstfahrende Erntemaschinen Gmbh | Verfahren zur Wartung und/oder Reparatur einer landwirtschaftlichen Arbeitsmaschine |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| CN114787180A (zh) | 2019-10-17 | 2022-07-22 | 斯特里迪比奥公司 | 用于治疗c型尼曼-匹克病的腺相关病毒载体 |
| MX2022004353A (es) | 2019-10-17 | 2022-07-19 | Casete de transferencia de aav. | |
| IL309560B2 (en) | 2019-12-06 | 2025-05-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
| IL325936A (en) * | 2020-01-22 | 2026-03-01 | Spark Therapeutics Inc | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| GB202002072D0 (en) | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| AU2021218703A1 (en) | 2020-02-14 | 2022-07-28 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating CDKL5 deficiency disorder |
| GB202003129D0 (en) | 2020-03-04 | 2020-04-15 | Hansa Biopharma AB | Conditioning regimen for transplant of stem cells |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| GB202007431D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| GB202007434D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| US20230277633A1 (en) | 2020-06-05 | 2023-09-07 | Shanghai Bao Pharmaceuticals Co., Ltd. | Pharmaceutical composition of enzymes and viruses and application thereof |
| WO2021254479A1 (zh) * | 2020-06-18 | 2021-12-23 | 上海宝济药业有限公司 | 一种免疫球蛋白降解酶IdeE的突变体 |
| JP2023542614A (ja) | 2020-08-19 | 2023-10-11 | サレプタ セラピューティクス， インコーポレイテッド | レット症候群の治療のためのアデノ随伴ウイルスベクター |
| CN120078887A (zh) * | 2020-09-21 | 2025-06-03 | 上海宝济药业股份有限公司 | 一种药物组合及其应用 |
| US20230374542A1 (en) | 2020-10-07 | 2023-11-23 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21) |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| FR3125965B1 (fr) * | 2021-08-05 | 2024-06-21 | Mc Saf | Conjugués anticorps-médicament |
| JP2024531138A (ja) | 2021-08-11 | 2024-08-29 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 筋ジストロフィーを処置するための組成物および方法 |
| EP4433587A2 (en) | 2021-11-15 | 2024-09-25 | Hansa Biopharma AB | Methods for enhancing adoptive cell transfer immunotherapies |
| JP2024546152A (ja) | 2021-12-16 | 2024-12-17 | 上海宝済薬業股▲ふん▼有限公司 | 免疫グロブリン分解酵素による切断に対抗するＦｃ変異体 |
| EP4275701A1 (en) | 2022-05-13 | 2023-11-15 | Hansa Biopharma AB | Conditioning regimen for cell transplant |
| EP4302770A1 (en) | 2022-07-08 | 2024-01-10 | Hansa Biopharma AB | Regimen for enzymatic desensitisation |
| WO2024057095A1 (en) | 2022-09-14 | 2024-03-21 | Genovis Ab | Mutant protease |
| EP4349365A1 (en) | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
| CN115873833B (zh) * | 2022-11-08 | 2024-08-16 | 上海泰昶生物技术有限公司 | 生产免疫球蛋白g降解酶的工程菌株和工艺 |
| CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
| AU2023383441A1 (en) | 2022-11-18 | 2025-06-05 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| WO2024148276A1 (en) | 2023-01-06 | 2024-07-11 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
| JP2026514409A (ja) * | 2023-03-29 | 2026-05-11 | サイラス バイオテクノロジー，インコーポレイテッド | ＩｄｅＳバリアントタンパク質及びそれを使用する方法 |
| WO2025103235A1 (zh) * | 2023-11-13 | 2025-05-22 | 上海宝济药业股份有限公司 | 一种免疫球蛋白降解酶IdeE的突变体 |
| WO2025226891A1 (en) * | 2024-04-26 | 2025-10-30 | Spark Therapeutics, Inc. | Nucleic acid encoding ides |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| CN118497176B (zh) * | 2024-07-16 | 2025-01-21 | 苏州康聚生物科技有限公司 | 一种免疫球蛋白降解酶 |
| GB202413764D0 (en) | 2024-09-18 | 2024-10-30 | Genovis Ab | Immunoglobulin proteases and their uses |
| GB202414654D0 (en) | 2024-10-04 | 2024-11-20 | Hansa Biopharma AB | Regimen for vector-based therapies |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| CA2235575A1 (en) * | 1995-10-23 | 1997-05-01 | Incyte Pharmaceuticals, Inc. | Novel human cysteine protease |
| CA2421278A1 (en) * | 1998-03-11 | 1999-09-16 | Genentech, Inc. | Novel polypeptides and nucleic acids encoding the same |
| EP1343895B1 (en) | 2000-12-21 | 2008-06-18 | ID Biomedical Corporation | Streptococcus pyogenes antigens and corresponding dna fragments |
| GB0130228D0 (en) | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| CN105770871A (zh) | 2005-06-09 | 2016-07-20 | 汉莎医药有限公司 | IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途 |
| GB0511769D0 (en) * | 2005-06-09 | 2005-07-20 | Hansa Medical Ab | Treatment |
| GB0624874D0 (en) * | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
| CN102584989B (zh) | 2007-09-14 | 2015-05-13 | 季诺维斯公司 | 用于解离Fcgamma-受体-IgG复合物及纯化与检测IgG的方法和试剂盒 |
| AU2008336295B2 (en) | 2007-12-13 | 2013-07-11 | Intervacc Ab | Improved immunizing composition |
| WO2009080278A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Stability testing of antibodies |
| WO2010089126A2 (en) | 2009-02-09 | 2010-08-12 | Roche Glycart Ag | Immunoglobulin glycosylation pattern analysis |
| EP3135684B1 (en) * | 2010-05-26 | 2023-06-28 | Intervacc AB | Vaccine against streptococcal infections based on recombinant fusion proteins |
| GB201115841D0 (en) | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| GB201316744D0 (en) | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
-
2015
- 2015-02-12 GB GB201502305A patent/GB201502305D0/en not_active Ceased
-
2016
- 2016-02-12 LT LTEPPCT/EP2016/053054T patent/LT3256579T/lt unknown
- 2016-02-12 PT PT167042233T patent/PT3256579T/pt unknown
- 2016-02-12 SI SI201631755T patent/SI3256579T1/sl unknown
- 2016-02-12 CA CA2976016A patent/CA2976016C/en active Active
- 2016-02-12 JP JP2017542900A patent/JP6879921B2/ja active Active
- 2016-02-12 RS RS20231088A patent/RS64840B1/sr unknown
- 2016-02-12 DK DK16704223.3T patent/DK3256579T5/da active
- 2016-02-12 ES ES16704223T patent/ES2962794T3/es active Active
- 2016-02-12 EP EP23180077.2A patent/EP4265719A1/en active Pending
- 2016-02-12 HR HRP20231496TT patent/HRP20231496T1/hr unknown
- 2016-02-12 EP EP16704223.3A patent/EP3256579B1/en active Active
- 2016-02-12 MY MYPI2017001125A patent/MY187486A/en unknown
- 2016-02-12 SG SG11201706349YA patent/SG11201706349YA/en unknown
- 2016-02-12 EA EA201791775A patent/EA035896B1/ru not_active IP Right Cessation
- 2016-02-12 MX MX2017010389A patent/MX391632B/es unknown
- 2016-02-12 HU HUE16704223A patent/HUE064122T2/hu unknown
- 2016-02-12 CN CN201680021602.2A patent/CN107532158A/zh active Pending
- 2016-02-12 KR KR1020177025524A patent/KR102524594B1/ko active Active
- 2016-02-12 AU AU2016217801A patent/AU2016217801B2/en active Active
- 2016-02-12 CN CN202110810280.2A patent/CN113564150B/zh active Active
- 2016-02-12 US US15/550,318 patent/US10758597B2/en active Active
- 2016-02-12 FI FIEP16704223.3T patent/FI3256579T3/fi active
- 2016-02-12 BR BR112017017286-0A patent/BR112017017286A2/pt not_active Application Discontinuation
- 2016-02-12 WO PCT/EP2016/053054 patent/WO2016128559A1/en not_active Ceased
- 2016-02-12 PL PL16704223.3T patent/PL3256579T3/pl unknown
-
2017
- 2017-07-27 ZA ZA2017/05114A patent/ZA201705114B/en unknown
- 2017-08-10 IL IL253939A patent/IL253939B/en active IP Right Grant
- 2017-08-11 CL CL2017002066A patent/CL2017002066A1/es unknown
- 2017-09-04 CO CONC2017/0009060A patent/CO2017009060A2/es unknown
-
2020
- 2020-02-17 US US16/792,747 patent/US11524057B2/en active Active
-
2022
- 2022-11-08 US US18/053,676 patent/US20230302100A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12359183B2 (en) | Cysteine protease | |
| US20230302100A1 (en) | Cysteine protease | |
| CN115698279B (zh) | 半胱氨酸蛋白酶 | |
| HK1240611A1 (en) | Cysteine protease | |
| HK1240611B (en) | Cysteine protease | |
| HK1240619A1 (en) | Cysteine protease | |
| HK1240619B (en) | Cysteine protease |